Fontan Protein-Losing Enteropathy: Dosing for a Leak, Not a Deficit
A college freshman with a Fontan circulation is losing immunoglobulin faster than his gut can be topped off by ordinary dosing. Standard immunodeficiency regimens assume the problem is production — his is disappearance, and that changes the actual math.
Marcus D. left for his freshman year at a state university four hundred miles from home three months ago, the first extended stretch of his life managing his own medication schedule and doctor's appointments without a parent double-checking either. Born with hypoplastic left heart syndrome, he completed his Fontan procedure at age three and had done well through childhood and adolescence, until swelling in his legs and unexplained weight loss during his first semester led his campus health center to check labs that came back with a serum albumin of 1.8 g/dL and an IgG of 210 mg/dL. His roommate first noticed the swelling before Marcus did, since he had gotten used to attributing his fatigue to a heavier course load than he'd taken in high school.
Stool alpha-1-antitrypsin clearance confirmed protein-losing enteropathy, a complication that develops in an estimated four to thirteen percent of Fontan patients within ten years of surgery, driven by elevated central venous pressure congesting the intestinal lymphatics and letting protein, including immunoglobulin, leak directly into the gut. He has had two sinus infections and one case of shingles since starting college, more than his entire high school infection history combined. Zaupper, Nielsen and Herlin, 2011, Congenital Heart Disease, treated four such patients and found the workable answer was not a larger single dose but a shorter one: a standard 1 g/kg replacement with the interval between infusions retitrated against albumin and gamma-globulin rather than fixed at four weeks, sustained over one to five years, with albumin rising and edema resolving. A 2019 case report at the American College of Allergy, Asthma and Immunology meeting made the same point from the other direction — an IgG of 222 mg/dL in a Fontan child who grew Streptococcus pneumoniae from blood — and concluded that aggressive dosing plus prophylaxis may be required, because the replaced immunoglobulin is being lost back into the gut rather than consumed at a normal rate. His prior cardiology team, four hours away, had never had reason to raise protein-losing enteropathy with him directly, since his Fontan physiology had never shown any warning sign of it before this semester.
Dosing for an ongoing leak, not a fixed deficit
His IgG of 210 with three infections in three months needs more than standard dosing math. Zaupper and colleagues dosed four Fontan patients with protein-losing enteropathy at a standard 1 g/kg but retitrated the interval against albumin and gamma-globulin instead of holding it at four weeks, and carried that for years with albumin rising and edema resolving. That is the shape of the fix here: he’s actively losing what we replace, not failing to make enough of it, so the interval is the lever, not the milligram figure. I want to increase both his dose and his infusion frequency.
I don't disagree he needs more immunoglobulin right now. What concerns me is treating dose escalation as the whole plan going forward — if his elevated central venous pressure is what's congesting his intestinal lymphatics in the first place, there's no dose of IVIG that outruns an ongoing leak with no ceiling on how much protein it can lose. I want a full hemodynamic workup, including catheterization, to see whether there's a fixable driver — a stenosis, an elevated Fontan pressure — before we settle into an indefinitely escalating dosing pattern.
Aggressive dosing is the right immediate answer to his infection risk — it isn't automatically the right long-term answer to why the leak exists in the first place.
There's no real conflict in timeline here. Start more frequent, higher-dose IVIG this week for his current infection risk — that doesn't wait on or interfere with a catheterization being scheduled in parallel. If the workup finds a correctable hemodynamic driver, the eventual dosing need may drop substantially; if it doesn't, we've lost nothing by having already protected him in the meantime.
Intensified immunoglobulin dosing started that week, with his campus health center coordinated to handle more frequent infusions closer to school rather than requiring travel home each time. Catheterization performed three weeks later identified a mild but real elevation in his Fontan pressure without a single correctable lesion.
Not agreed: whether that finding argues for pursuing further interventional options to lower his Fontan pressure directly, as the cardiologist leans toward, or whether intensified immunoglobulin dosing indefinitely is the more realistic long-term plan given the absence of one clear fixable lesion — left open pending his response to the current regimen over the next several months.